Longevity Goes Global: How Singapore’s Bold Vision and Australia’s i-Screen Are Rewriting the Future of Preventative Health
A quiet shift is underway in global health — not in the emergency room, but long before anyone ever steps inside one. Across Australia, people managing chronic fatigue syndrome, autoimmune issues, and pre-diabetes have already begun using tools like i-Screen to unravel the biochemical stories shaping their daily lives.
Now, that movement is colliding with an even bigger wave building across Asia, where Singapore has decided that longevity isn’t a luxury. It’s a national project.
While Silicon Valley health unicorns like Function Health dominate headlines — its recent raise pushing its valuation to US$2.5 billion — the real centre of gravity may be shifting eastward. Singapore is emerging as Asia’s longevity epicentre, a place where government foresight, academic firepower, and tech innovation converge with almost architectural precision.
And in the middle of this surge? The very same Australian-born disruptor that made personalised blood analytics accessible and affordable for everyday people: i-Screen.
Note: 1EarthMedia may earn a commission for signing new customers to i-Screen via links on this page.
Advertisement:
The Health Revolution That Started with a Blood Test
For Australians grappling with fatigue, thyroid problems, inflammation, pre-diabetes, high cholesterol, CFS, long COVID, osteoporosis, autoimmune disorders and the mysterious bundle of symptoms that often arrive with age, i-Screen changed the rules. No more guessing whether iron levels had tanked or whether inflammation markers were creeping up. No more waiting months for GP referrals.
A simple online order. A visit to one of 3,000 collection centres. Results in a personalised dashboard interpreted by medical doctors.
Affordable, clinical-grade insight — starting at just $15 — and suddenly people could track their health the way they track their finances.
i-Screen gave chronic-condition communities something they rarely receive: agency.
Singapore Scales That Vision Into a National Blueprint
Singapore looked at this model and saw not just a startup, but a strategy.
The city-state recently committed an eye-watering S$37 billion under its RIE 2030 plan — money explicitly aimed at healthy longevity, precision medicine, and geroscience. This isn’t a marketing line; it’s structural.
Biopolis, the biotech city-within-a-city, is rapidly becoming the beating heart of Asia’s longevity research. And with Asia’s senior population set to exceed 1 billion people by 2050, Singapore is engineering solutions at continental scale.
Academically, the National University of Singapore (NUS) is the region’s powerhouse, shifting geromedicine from reactive care (“fix disease when it appears”) to proactive intervention (“slow aging before it manifests”).
The Academy for Healthy Longevity has launched clinical trial centres, partnered with global players like Abbott and Haleon, and produced research showing public appetite for subsidised, preventative screening. Singaporeans aren’t waiting for illness — they want healthspan, not just lifespan.
Advertisement:
Enter i-Screen: From Perth to Asia’s Growth Engine
For i-Screen, the move into Singapore was less expansion and more destiny.
Already serving more than 113,000 users, i-Screen launched i-screen.sg on December 9, 2025, officially establishing Singapore as its Southeast Asia headquarters. Under new CEO Scott Montgomery, the company is expanding into high-growth sectors like integrative medicine, TCM-aligned wellness insights, and data-driven longevity screening.
In Australia, i-Screen empowered older adults and people with chronic conditions to understand fatigue, inflammation, insulin resistance, vitamin deficiencies, hormone imbalance, and cardiovascular risk before they spiralled into serious illness.
In Singapore, that offering evolves into a broader suite:
- Biological age assessments
- Longevity-related genetic screening
- Precision nutrition based on biomarkers
- Microbiome analysis
- Dashboards that unify health data into a single, continuous story
For a region of 4.7 billion people increasingly wealthy, increasingly health-literate, and increasingly motivated to extend quality of life, this is fuel on the fire.
A Perfect Storm of Demand
Asia’s appetite for preventative health blends the ancient and the ultramodern:
- TCM practitioners and wellness clinics want biomarker insights.
- Fitness coaches are building data-driven transformation programs.
- Insurers are pivoting toward prevention-based coverage.
- Consumers want dashboards, not diagnoses.
Singapore is the testbed where these worlds collide — and i-Screen is one of the companies ensuring clinical quality meets consumer accessibility.
Advertisement:
Why This Matters for Everyday People
What started as an Australian tool for managing chronic illness is now part of a global longevity wave. For anyone living with CFS, autoimmune issues, thyroid dysfunction, pre-diabetes, high blood pressure, or the cocktail of conditions that often appear after 50, this trend offers unprecedented opportunity:
- earlier detection
- personalised interventions
- more control over your health trajectory
- fewer medical surprises
We are moving from “What’s wrong with me?” to “What does my body need next?”
From “I hope I don’t get sick” to “I’m on top of this.”
From treatment to prevention. From lifespan to healthspan.
The Race Is On — and Singapore Wants to Win It
Singapore isn’t merely participating in the longevity boom. It’s choreographing it — a fusion of science, government, business, and culture designed to fundamentally shift how billions of people age.
The next unicorns won’t just count steps or calories. They’ll track inflammation, cellular aging, metabolic resilience, and recovery — the real predictors of long-term wellbeing.
With regulatory agility, world-class talent, and a population ready for preventative care, Singapore is primed to lead Asia’s trillion-dollar longevity era.
And i-Screen, born in Perth, honed in Australia’s crowded health landscape, now sits on the front row of that future — turning simple blood tests into a global movement toward living longer, living stronger, and living smarter.
The question now isn’t whether longevity innovation will reshape Asia.
It’s which companies — and which countries — will keep up.
Singapore has raised its hand. i-Screen is already in the room.
Note: 1EarthMedia may earn a commission for signing new customers to i-Screen via links on this page.
Related stories
Longevity, Health & Plant Power by Professor Luigi Fontana
Smarter Ageing: How Tech and Training Will Redesign Care
Immutep’s Research into Cancer and Autoimmune Treatment
History, Variations and Health Benefits of Pho Soup
“Made in USA” Isn’t the Food Safety Stamp It Used to Be
Ozempic, Wegovy & GLP-1 Weight Loss Drugs & Food’s New Future
Advertisement:
